Clemastine fumarate shows promise as a remyelinating agent for multiple sclerosis
- Posted on: Jan 11 2018
- Leave a response
This phase 2 clinical trial (ReBUILD) evaluated the use of clemastine fumarate—a first-generation antihistamine capable of inducing oligodendrocyte differentiation—as a remyelinating therapy for patients with multiple sclerosis.
Source: AAO
Posted in: Uncategorized